Management of Atrial Flutter – Evidence‑Based Recommendations

Acute Ventricular Rate Control (Hemodynamically Stable Patients)

Intravenous or oral beta‑blockers, diltiazem, or verapamil are first‑line agents for rapid ventricular response control in stable atrial flutter. Class I recommendation (AHA). 1
In patients with systolic heart failure who cannot receive beta‑blockers, intravenous amiodarone may be used (avoid if pre‑excitation is present). Class IIa recommendation (AHA). 1

Indicated for stable patients when a rhythm‑control strategy is desired. Class I recommendation (AHA). 1
Must be performed immediately in hemodynamically unstable patients who do not respond to pharmacologic therapy. Class I recommendation (AHA). 1

Oral dofetilide or intravenous ibutilide are effective for acute conversion of atrial flutter. Class IIa recommendation (AHA). 1
Flecainide, propafenone, and dofetilide are also effective, with contraindications in structural heart disease. Class IIa recommendation (AHA). 5

Rapid atrial pacing can achieve acute conversion in patients with a permanent pacemaker, implantable cardioverter‑defibrillator, or temporary atrial pacing post‑cardiac surgery. Class IIa recommendation (AHA). 1

Antithrombotic management for atrial flutter follows the same guidelines as for atrial fibrillation (CHA₂DS₂‑VASc‑based). Class I recommendation (ACC). 7

Flutter duration	Anticoagulation strategy before/after cardioversion
≥ 48 h or unknown	Warfarin (INR 2.0–3.0) for ≥ 3 weeks pre‑ and ≥ 4 weeks post‑cardioversion.	[5]
< 48 h, low thrombo‑embolic risk	IV heparin, LMWH, direct Xa inhibitor, or direct thrombin inhibitor administered as soon as possible before or immediately after cardioversion.	[5]
Immediate cardioversion desired	Transesophageal echocardiography to exclude left‑atrial thrombus, followed by unfractionated heparin and transition to oral anticoagulation.	[7]
Hemodynamic instability	Immediate cardioversion; start anticoagulation promptly and continue for ≥ 4 weeks.	[5]

Class I indication: Symptomatic or drug‑refractory atrial flutter; CTI‑independent recurrent flutter after failure of at least one antiarrhythmic. Class I recommendation (AHA). 1
Class IIa indications:
- CTI‑dependent flutter precipitated by flecainide, propafenone, or amiodarone used for atrial fibrillation.
- Patients undergoing atrial fibrillation ablation with documented CTI‑dependent flutter.
- CTI‑independent symptomatic recurrent flutter considered before antiarrhythmic drugs. Class IIa recommendation (AHA). 1
Class IIb indication: May be considered in asymptomatic patients with recurrent flutter. Class IIb recommendation (AHA). 1

Beta‑blockers, diltiazem, or verapamil are appropriate for rate control in patients with tolerated flutter. Class I recommendation (AHA). 1
A permissive resting heart‑rate target < 110 bpm is reasonable when patients remain asymptomatic and left‑ventricular systolic function is preserved. Class IIa recommendation (AHA). 8

Amiodarone – effective for maintaining sinus rhythm; monitor for long‑term extracardiac toxicity. Class I recommendation (AHA). 1
Dofetilide and sotalol – useful alternatives. Class IIa recommendation (AHA). 1
Flecainide or propafenone – appropriate in patients without structural heart disease or ischemic coronary disease. Class IIa recommendation (AHA). 1

Ongoing antithrombotic therapy should be guided by CHA₂DS₂‑VASc risk stratification, identical to atrial fibrillation management, irrespective of rhythm‑maintenance strategy. Class I recommendation (ACC). 1

22–50 % of patients develop atrial fibrillation within 14–30 months after CTI ablation. Risk factors include prior atrial fibrillation, left‑ventricular dysfunction, structural heart disease, and enlarged left atrium. Class IIa recommendation (AHA). 1